Literature DB >> 7494109

Human antibodies from transgenic mice.

N Lonberg1, D Huszar.   

Abstract

We have used homologous recombination in ES cells to engineer B cell-deficient mice that are incapable of expressing endogenous immunoglobulin heavy and kappa light chain genes. We find that B cell development in these mutant mice can be rescued by the introduction of human germline-configuration heavy- and kappa light-chain minilocus transgenes. The transgenes rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation in response to antigen stimulation; thus recapitulating both stages of the humoral immune response using human, rather than mouse, sequences. The mice can be immunized; and human sequence, antigen specific, monoclonal antibodies can be obtained using conventional rodent hybridoma technology. These animals are also of interest for studying the normal processes of immunoglobulin gene expression. We discuss the example of heavy chain class switching, which has not been previously observed within an autonomous transgene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494109     DOI: 10.3109/08830189509061738

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  18 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

Review 2.  Selection and characterization of cell binding and internalizing phage antibodies.

Authors:  Yu Zhou; Lequn Zhao; James D Marks
Journal:  Arch Biochem Biophys       Date:  2012-05-22       Impact factor: 4.013

3.  Year of the ox.

Authors:  Yann Echelard
Journal:  Nat Biotechnol       Date:  2009-02       Impact factor: 54.908

Review 4.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 5.  Targeting B cells for the treatment of rheumatoid arthritis.

Authors:  Thomas J Oligino; Stacie A Dalrymple
Journal:  Arthritis Res Ther       Date:  2003-10-02       Impact factor: 5.156

Review 6.  Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Authors:  Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

Review 7.  Gene targeting in livestock: a preview.

Authors:  A J Clark; S Burl; C Denning; P Dickinson
Journal:  Transgenic Res       Date:  2000       Impact factor: 3.145

8.  Expression of recombinant antibodies.

Authors:  André Frenzel; Michael Hust; Thomas Schirrmann
Journal:  Front Immunol       Date:  2013-07-29       Impact factor: 7.561

Review 9.  Specific genetic modifications of domestic animals by gene targeting and animal cloning.

Authors:  Bin Wang; Jiangfeng Zhou
Journal:  Reprod Biol Endocrinol       Date:  2003-11-13       Impact factor: 5.211

10.  Isolation of recombinant antibodies directed against surface proteins of Clostridium difficile.

Authors:  Ali Nazari Shirvan; Robert Aitken
Journal:  Braz J Microbiol       Date:  2016-03-02       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.